The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Open accessAbstract
BACKGROUND: Patients with diabetes are at higher risk for death and cardiovascular outcomes than the general population. We investigated whether the excess risk of death and cardiovascular events among patients with type 2 diabetes could be reduced or eliminated. METHODS: In a cohort study, we included 271,174 patients with type 2 diabetes who were registered in the Swedish National Diabetes Register and matched them with 1,355,870 controls on the basis of age, sex, and county. We assessed patients with diabetes according to age categories and according to the presence of five risk factors (elevated glycated hemoglobin level, elevated low-density lipoprotein cholesterol level, albuminuria, smoking, and elevated blood pressure). Cox regression was used to study the excess risk of outcomes (death, acute myocardial infarction, stroke, and hospitalization for heart failure) associated with smoking and the number of variables outside target ranges. We also examined the relationship between various risk factors and cardiovascular outcomes. RESULTS: The median follow-up among all the study participants was 5.7 years, during which 175,345 deaths occurred. Among patients with type 2 diabetes, the excess risk of outcomes decreased stepwise for each risk-factor variable within the target range. Among patients with diabetes who had all five variables within target ranges, the hazard ratio for death from any cause, as compared with controls, was 1.06 (95% confidence interval [CI], 1.00 to 1.12), the hazard ratio for acute myocardial infarction was 0.84 (95% CI, 0.75 to 0.93), and the hazard ratio for stroke was 0.95 (95% CI, 0.84 to 1.07). The risk of hospitalization for heart failure was consistently higher among patients with diabetes than among controls (hazard ratio, 1.45; 95% CI, 1.34 to 1.57). In patients with type 2 diabetes, a glycated hemoglobin level outside the target range was the strongest predictor of stroke and acute myocardial infarction; smoking was the strongest predictor of death. CONCLUSIONS: Patients with type 2 diabetes who had five risk-factor variables within the target ranges appeared to have little or no excess risk of death, myocardial infarction, or stroke, as compared with the general population. (Funded by the Swedish Association of Local Authorities and Regions and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“when all major cardiovascular risk factors are treated to within the target ranges, people with type 2 diabetes have risk of death, MI, or stroke similar to that of the general population (6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among persons with type 2 diabetes (T2D), cardiovascular risk and mortality are dependent on the number of uncontrolled risk factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the evidence from prospective intervention studies to support comprehensive ASCVD risk factor reduction, a large cohort study confirmed no or only marginally increased mortality, MI, and stroke risk compared with the general population when all major cardiovascular risk factors are managed to goal levels in people with type 2 diabetes (6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Hypertriglyceridemia is indirectly linked with changes in HDL-C and LDL-C composition that are conducive to accelerated atherogenesis.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In persons with fasting triglycerides of 200 to 499 mg/dL, despite tight adherence to a healthy diet (to include reduced intake of simple carbohydrates and avoidance of fruit juices and alcohol) and optimized glycemia control, prescribe statin therapy to the maximum tolerated dose to achieve goals for non-HDL-C or apo B, since all apo B–containing particles are potentially atherogenic.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“To date, aside from icosapent ethyl, fish oil therapy has not been shown to prevent CV adverse events.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“No RCT has yet been reported to investigate the benefit of reducing severe (>500 mg/dL) or moderate (>200 mg/dL) hypertriglyceridemia to prevent CVD.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite these newer therapies, the risk of kidney failure remains high, particularly in those whose risk factors are insufficiently controlled.6,7”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“In patients with advanced disease, e.g.T2DM and established microalbuminuria, an intensive, target-driven, multifactorial therapy (Steno-2 study; targets: HbA1c <6.5%, total cholesterol <4.5 mmol/L [175 mg/dL], and BP <130/80 mmHg) resulted in 50% fewer microvascular and macrovascular events after 7.8 years of follow-up.361”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [361]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citation
Cited by
Sorted by citations
Items 801–900 of 999
Poorrezaei, M., Zakeri, M. A., Kamiab, Z., Shafiepour, M., Khalili, P., Hermis, A. H., Hajwal, S. K., Jawed, I., & Karimifard, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-31797-2 · Cited by 6
Kavanagh, M. E., del Real, I. H., Priéto, I., Alvarez-Moreno, R., Egido, J., López‐Franco, Ó., Lázaro, I., & Gómez‐Guerrero, C. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03121-3 · Cited by 4
Yang, J., Zhang, J. I. A. N., Huang, R., Meng, K., Liang, J.-J., Lin, J., Wang, J., Wang, Y., Gao, Y., Qu, Y., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104228 · Cited by 5
Ko, B., Jung, C., Ko, Y. E., Koh, H. B., Park, C. H., Kim, H. W., Park, J. T., Han, S. H., Kang, S. M., Kim, J., et al. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001078 · Cited by 7
Baldissera, S., Minardi, V., Masocco, M., & Ferrante, G. (2022) · European Journal of Public Health · doi:10.1093/eurpub/ckac037 · Cited by 3
Trends in Survival After First Myocardial Infarction in People With Diabetes
Glynn, L., Lind, M., Andersson, T., Eliasson, B., Hofmann, R., & Nyström, T. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034741 · Cited by 4
Self-citationSun, L. Y., Yuan, J., Wang, T., Ning, B., & Yuan, Q. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1475063 · Cited by 4
Vershinina, O., Sabbatinelli, J., Bonfigli, A. R., Colombaretti, D., Giuliani, A., Krivonosov, M., Trukhanov, A., Franceschi, C., Ivanchenko, M., & Olivieri, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1689312 · Cited by 4
Cardiovascular Risk Prediction – Are we Missing Something?
Gallagher, J., Watson, C. J., Ledwidge, M. T., & McDonald, K. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1901 · Cited by 4
Chen, S., Yang, F., Xu, T., Wang, Y., Zhang, K., Fu, G., & Zhang, W. (2021) · Nutrition Journal · doi:10.1186/s12937-021-00735-z · Cited by 4
Hyaluronan Inhibition as a Therapeutic Target for Diabetic Kidney Disease: What Is Next?
Salman, L. H., Martinez, L., Faddoul, G., Manning, C., Ali, K., Salman, M., & Vázquez-Padrón, R. I. (2023) · Kidney360 · doi:10.34067/kid.0000000000000126 · Cited by 3
Tang, J., Yang, Z., Kee, F., & Congdon, N. G. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1101909 · Cited by 4
Sabino, T. B. M., Vancea, D. M. M., Costa, M. D. C., Melo, R. J. P., Dantas, I. V., & Ribeiro, J. N. D. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110676 · Cited by 4
Vemulapalli, H. S., Vajje, J., Rehman, W. U., Virk, G. S., Shah, K., Chaudhari, S. S., MIAN, I.-U.-D., & Saleem, F. (2023) · Cureus · doi:10.7759/cureus.45421 · Cited by 4
Myocardial Calcium Handling in Type 2 Diabetes: A Novel Therapeutic Target
Dattani, A., Singh, A., McCann, G. P., & Gulsin, G. S. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11010012 · Cited by 5
Temesgen, R., Asefa, H., gezahagn, Y., Abebe, G., & Hailu, T. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001951 · Cited by 4
Chen, T., Shao, D., Zhao, J., Xiu, M., Li, Y., He, M., Tan, Y., An, Y., Zhang, X., Zhao, J., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1368743 · Cited by 4
Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice
Bafna, A. A., Mehta, A., Garg, R., Balagopalan, J. P., Rajput, R., Zalte, N., Naik, P., Sugumaran, A., & Mohanasundaram, S. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_115_23 · Cited by 4
TET3 Contributes to Exercise‐Induced Functional Axon Regeneration and Visual Restoration
Fang, S., Ji, Y., Shen, Y., Yang, S., Zhang, H., Xin, W., Shi, W., & Chen, W. (2024) · Advanced Biology · doi:10.1002/adbi.202400145 · Cited by 5
Insights to the emerging potential of glucokinase activators as antidiabetic agent
Mehra, A., Kumar, S., Mittal, A., Kohli, R., & Mittal, A. (2024) · Pharmaceutical Patent Analyst · doi:10.1080/20468954.2024.2389762 · Cited by 4
Chevalier, C., Oliveira, A. R., Blanchard, V., May, C. L., Cariou, B., Hadjadj, S., & Croyal, M. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101683 · Cited by 4
Predictors of 15-year survival among Australian women with diabetes from age 76–81
Wubishet, B. L., Harris, M. L., Forder, P., Acharya, S., & Byles, J. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.016 · Cited by 4
Escobar, P. M., Sakem, B., Risch, L., Risch, M., Grebhardt, C., Nydegger, U. E., & Stanga, Z. G. (2019) · Swiss Medical Weekly · doi:10.4414/smw.2019.20163 · Cited by 4
Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes
Patel, K. V., & Vaduganathan, M. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000762 · Cited by 4
Kao, Y.-C., Chen, T., Liu, C., Hwang, J., Hsiao, C.-C., Lin, Y., Mao, C., Hung, M., & Li, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-86090-9 · Cited by 4
Uy, A. B., & Jimeno, C. (2021) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.036.01.02 · Cited by 6
Krittayaphong, R., Aroonsiriwattana, S., Ngamjanyaporn, P., Patmuk, T., Kaewkumdee, P., & for the COOL‐AF Investigators (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14671 · Cited by 4
Lyu, F., Cai, X., Lin, C., Hong, T., Zhang, X., Lu, J., Guo, X., Wang, Z., Xing, H., Zong, G., et al. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001741 · Cited by 6
Guillén-Aguinaga, S., Forga, L., Brugos‐Larumbe, A., Guillén‐Grima, F., Guillén-Aguinaga, L., & Aguinaga-Ontoso, I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245854 · Cited by 5
Wang, X., Han, Y. H., Xiao, E., Zhang, K., & Ma, Y. (2021) · Journal of Biobased Materials and Bioenergy · doi:10.1166/jbmb.2021.2068 · Cited by 4
Ileal Interposition with Sleeve Gastrectomy for Type 2 Diabetes Mellitus and Metabolic Syndrome
DePaula, A. L., Ugale, S. M., Branco, A., Dutra, C. C. L. P., Ugale, A., Ugale, A., & Çelik, A. (2023) · Springer eBooks · doi:10.1007/978-3-030-60596-4_58 · Cited by 4
Relative importance of potential risk factors for dementia in patients with hypertension
Jung, M., Kim, K., Lee, J. H., & Sung, K. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281532 · Cited by 4
Shan, J., & Xu, Z. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15093 · Cited by 4
Lavigne, A., Nguyen, D. L., Chartrand-Oberoi, O., Noyon, B., Spiliotopoulos, S., Kfoury, C., Vanasse, L., Chamieh, R., Bouhadana, H., Boudier‐Revéret, M., et al. (2023) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000002300 · Cited by 4
Xu, Y., Qin, Z., Gao, J., Yang, Y., Lu, Y., Yu, F., Lv, Y., Sun, Z., Zhang, J., & Tang, J. (2023) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2023.0051 · Cited by 4
Dejby, E., Bhatt, D. L., Skoglund, K., Rawshani, A., Ömerovic, E., Redfors, B., Myredal, A., Pétursson, P., Angerås, O., Gustafsson, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39570-z · Cited by 4
Self-citationMaladie rénale chronique et diabète de type 2. Histologie, pathogénie et stades évolutifs
Monnier, L., Halimi, S., & Colette, C. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.10.003 · Cited by 4
Exploring QRS Area beyond Patient Selection in CRT—Can It Guide Left Ventricular Lead Placement?
Eerenberg, F., LUERMANS, J. G. L. M., Lumens, J., Nguyên, U. C., Vernooy, K., & van Stipdonk, A. M. W. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11010018 · Cited by 4
Dimnjaković, J., Buble, T., Ivanko, P., Pristaš, I., Brborović, O., & Brborović, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-57871-9 · Cited by 4
Demidova, T. Y., & Izmaylova, M. Y. (2024) · FOCUS Endocrinology · doi:10.15829/2713-0177-2024-5-1-01 · Cited by 4
For debate; pharmacological priorities in advanced type 2 diabetes
Hodish, I. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107510 · Cited by 4
Chen, H.-H., Wu, C., Tsai, Y., Ho, C.-W., Hsieh, M., & Lai, J. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/1298487 · Cited by 4
Koskinas, K. C., Melmer, A., Steiner, N., Gübeli, A., Wilhelm, M., & Laimer, M. W. (2021) · Praxis · doi:10.1024/1661-8157/a003589 · Cited by 4
Dutta, P., Nayak, V. K. R., & Punja, D. (2021) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2021.10.002 · Cited by 4
Pujante, P., Torre, E. L. M., Morales-Sánchez, P., Escobedo, R. R., Barreiro, S. C., Rojo‐Martínez, G., & Delgado, E. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.12.040 · Cited by 4
Cardiac rehabilitation underutilization: Missed opportunities in comprehensive cardiac care
KONES, R. J., Morales, A., & Rumana, U. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.05.068 · Cited by 4
Bennett, A. B., & Stockley, H. L. (1974) · PubMed Central · Cited by 4
Ahmad, A., Lim, L., Morieri, M. L., Tam, C. H. T., Cheng, F., Chikowore, T., Dudenhöffer‐Pfeifer, M., Fitipaldi, H., Huang, C., Kanbour, S., et al. (2023) · medRxiv · doi:10.1101/2023.04.26.23289177 · Cited by 4
Arenas-León, J. L., Morales-Villegas, E., Cardona-Muñóz, E. G., Alcocer-Gamba, M. A., Ramirez-Contreras, J. P., Contreras-Sandoval, A. Y., & González-Gálvez, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01231-6 · Cited by 4
Kim, S., & Jeon, B. (2024) · BMC Public Health · doi:10.1186/s12889-024-19690-5 · Cited by 3
Prato, S. D., Li, Z., Ramasundarahettige, C. F., Branch, K. R., Lam, C. S. P., Lópes, R. D., Pratley, R. E., Rosenstock, J., Sattar, N. A., & Gerstein, H. C. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02432-7 · Cited by 3
Self-citationCai, Y., Liu, F.-H., Sun, J., & Lin, C. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.016 · Cited by 3
Kunina, H., Franzén, S., & Kjellsson, M. C. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13301 · Cited by 3
Self-citationRen, W., Fan, K., Liu, Z., Wu, Y., An, H., & Liu, H. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70049 · Cited by 3
Green, H., Zhang, Y. S., Li, C., Zaninotto, P., Langa, K. M., Lee, J., Manne-Goehler, J., & Flood, D. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004678 · Cited by 3
Jeffrey, T., FLETCHER, R. A., Arnott, C. G., Jun, M., KOTWAL, S. S., Perkovic, V., Badve, S. V., & NEUEN, B. L. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.05.021 · Cited by 3
Song, J. T., Kang, Y., Wang, L., Guo, Y., Jia, X., Dong, S., Li, Y., Wang, D., Gao, J., & Yang, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329965 · Cited by 4
Yan, H., Xiang, Y., Jiang, B., Sang, X., Xiang, Y., & Yuan, R. (2025) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2025.138698 · Cited by 3
Loneliness, social isolation and stroke risk in men and women with and without diabetes
Xiu, W., Zu, Y., Wang, X., & Yoshida, Y. (2025) · BMC Public Health · doi:10.1186/s12889-025-24458-6 · Cited by 3
Trenell, M. I., Robles, M. C., Taylor, L., Northway, N., Kerr, K. W., Lumsden, C., Avery, L., Faluyi, D., Rueda, R., & SULO, S. S. (2025) · Clinical Diabetes · doi:10.2337/cd25-0054 · Cited by 4
Comprehensive risk factor control in Type 2 diabetes and incident peripheral artery disease
Yu, X., Lian, Z., Wu, J., Tang, P., & Xiong, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf697 · Cited by 3
Xue, H., Wang, L., Wu, Y., Liao, Y., Wang, S., Chen, A., Chan, S. O., Ling, W., Chen, X., & Yu, C. (2025) · Hepatology · doi:10.1097/hep.0000000000001628 · Cited by 4
Qiu, Z., Qian, F., Zhang, Y., Liu, J., Geng, T., Li, R., Yao, P., Franco, O. H., Rimm, E. B., Manson, J. E., et al. (2025) · Military Medical Research · doi:10.1186/s40779-025-00674-4 · Cited by 4
Web-based cardiovascular disease risk prediction using machine learning
Akhter, S., & Miller, J. H. (2026) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2026.1690664 · Cited by 6
Cardiovascular-Kidney-Metabolic Syndrome: Development of an ICD-10-CM Coding Framework
ZHAO, M., Zhang, J., Wang, H., Xu, C., Li, J., Li, C., He, X., & Zheng, X. (2026) · JMIR Diabetes · doi:10.2196/91827 · Cited by 4
Lopes, A. C., Lourenço, O. M., Roque, F., & Morgado, M. (2023) · Biomedicines · doi:10.3390/biomedicines11020256 · Cited by 4
Dual GLP-1/GIP Agonist Tirzepatide for Diabetes and Obesity: A Review of the Evidence
Wardeh, R., Elbo-Iswadi, T. H., Alsharayri, H. M. H., Rashid, F., Alhashemi, N., & Bashier, A. M. (2023) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0043-1775966 · Cited by 4
Sasaki, N., Maeda, R., Ozono, R., Yoshimura, K., Nakano, Y., & Higashi, Y. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003671 · Cited by 3
Zhang, A., Kalil, R. K., Marzec, A., Coulter, S., Virani, S. S., Patel, K. V., & Segar, M. W. (2024) · Texas Heart Institute Journal · doi:10.14503/thij-23-8375 · Cited by 4
Cai, J., Peng, P., Lu, J., Shen, Y., Wang, C., Mo, Y., Lu, W., Zhu, W., Xia, T., & Zhou, J. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3813 · Cited by 3
Hajhashemy, Z., Ziaei, R., Askari, G., & Saneei, P. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae060 · Cited by 3
Mukonda, E. E., Lesosky, M., Sithole, S., van der Westhuizen, D. J., Rusch, J. A., Levitt, N. S., MYERS, B. J., & Cleary, S. (2024) · Health Policy and Planning · doi:10.1093/heapol/czae072 · Cited by 3
Park, C. S., Choi, J., Kwak, S., Lee, S., Kim, H., Kim, Y.-J., Kwak, S. H., & Park, J. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004244 · Cited by 7
Sattler, E. L. P., Lassale, C. M., Diaw, M., Joseph, J. J., Singh, G., Samb, A., Lloyd‐Jones, D. M., & Gaye, B. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101450 · Cited by 3
Golden, F., Tran, J., & Wong, N. D. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100939 · Cited by 6
Shestakova, M. V., Galstyan, G. R., Kvasnikov, B. B., & Erina, E. E. (2025) · Diabetes Mellitus · doi:10.14341/dm13244 · Cited by 3
Avogaro, A., Buzzetti, R., Candido, R., Cosmo, S. D., Notarianni, L., Consolo, E., & Luciano, M. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112055 · Cited by 3
Falcetta, P., Zilich, R., Baccetti, F., Baronti, W., Masi, D., Morviducci, L., Musacchio, N., Muselli, M., Ozzello, A., Rossi, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf229 · Cited by 3
Wu, S., Wu, Y., Ning, Y., Peng, X., Zhao, H., Feng, J., Lin, L., Ruan, C., Chen, S., Tian, J., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.041223 · Cited by 4
Garberg, G., Boström, K. B., Hjerpe, P., Ayala, M. N., Adrian, M. L., & Andersson, T. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005356 · Cited by 5
Al-Shamsi, S., Govender, R. D., & Soteriades, E. S. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-032654 · Cited by 3
Die Behandlung des Diabetes mellitus: Mythen und Evidenz
Göke, B. (2020) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-020-03124-9 · Cited by 4
Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug
Petunina, N. A., Кузина, И. А., & Недосугова, Л. В. (2020) · Diabetes Mellitus · doi:10.14341/dm12487 · Cited by 3
Use of cardiovascular imaging in risk restratification of the diabetic patient
Bellinge, J. W., Lee, S. C., & Schultz, C. J. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000611 · Cited by 3
Quality of Diabetes Care in the USA
Alencherry, B., & Bruemmer, D. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01503-5 · Cited by 3
Clinical Use and Limitation of Hemoglobin A1c Examination
Suastika, K. (2021) · Clinical Diabetology · doi:10.5603/dk.a2021.0045 · Cited by 5
Afzal, B., Ali, S. A., & Jamil, B. (2021) · Cureus · doi:10.7759/cureus.19935 · Cited by 3
Nodari, S., Fioretti, F., & Barillà, F. (2022) · Heart Failure Reviews · doi:10.1007/s10741-021-10203-9 · Cited by 3
Hoffmann, A. P., & Honigberg, M. C. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01024-8 · Cited by 3
Shaikh, K. A., Ahmed, A., Gransar, H., Lee, J. H., Leipsic, J. A., Nakanishi, R., Alla, V. M., Bax, J. J., Chow, B. J. W., Berman, D. S., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108309 · Cited by 3
Rasooly, D., Yang, Q., Moonesinghe, R., Khoury, M. J., & Patel, C. J. (2022) · Public Health Genomics · doi:10.1159/000526242 · Cited by 3
Mortality attributable to cardiovascular diseases in young adults residents in Brazil
Ribeiro, S. D. L., Macedo, H., Adami, F., Santos, E. F. D. S., Bernal, H. D. M., Morais, T. C., Smiderle, F. R. N., Pimentel, R. M. M., & Venâncio, D. P. (2022) · Journal of Human Growth and Development · doi:10.36311/jhgd.v32.13328 · Cited by 3
Vidal‐Petiot, E., Elbez, Y., Mesnier, J., Ducrocq, G., Ford, I., Tendera, M., Ferrari, R., Tardif, J., Fox, K. M., & Steg, P. G. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad004 · Cited by 3
Diabetes and Cardiovascular Disorder
Priya, S. S., & Ebenezar, K. K. (2023) · Springer eBooks · doi:10.1007/978-981-19-0027-3_3 · Cited by 3
Rauchen, erhitzte Tabakprodukte, Alkohol und Diabetes mellitus (Update 2023)
Brath, H., Kaser, S., Tatschl, C., Fischer-See, S., & Fasching, P. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02161-z · Cited by 5
Sow, M. A., Treiber, G., Cosson, E., Mutunzi, Y., Magné, J., Boulogne, C., Salle, L., Boukhris, M., Nobécourt, E., & Aboyans, V. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110871 · Cited by 3
The Physiological and Molecular Links Between Physical Activity and Brain Health: A Review
Schock, S., & Hakim, A. M. (2023) · Neuroscience Insights · doi:10.1177/26331055231191523 · Cited by 7
Role of Polyphenols in Cardiovascular Diseases
Chopra, H., Bibi, S., Mohanta, Y. K., Kumari, S., & Baig, A. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-28780-0_35 · Cited by 3
dos Santos, I. M. R., Rolim, I. L. T. P., Júnior, A. D., Loureiro, M. A. B., da Silva, D. M. B., & Lopes, G. S. G. (2024) · Aquichan · doi:10.5294/aqui.2024.24.1.2 · Cited by 3
França, G. R., Rosa, V. S., Rezende, . . H. M., Filho, M. D. E. C., Jansen, H. E. M., Filho, D. J. D. S., Pereira, B. M., Alves, N. C., Pinotti, J. G. F., de Araújo, M. A. A., et al. (2024) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2024v6n4p577-589 · Cited by 5
Metadata
- Authors
- Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., & Gudbjörnsdottir, S.
- Affiliations
- Uppsala University (SE)
- From the Department of Molecular and Clinical Medicine, Institute of Medicine (Aidin Rawshani, Araz Rawshani, B.E., A. Rosengren, S.G.), and the Health Metrics Unit, Sahlgrenska Academy (S.F.), University of Gothenburg, and the Swedish National Diabetes Register, Center of Registers in Region (Aidin Rawshani, Araz Rawshani, S.F., B.E., A.-M.S., M.M., S.G.), Gothenburg, and the Department of Public Health and Caring Sciences–Geriatrics, Uppsala University, and the Swedish Medical Products Agency,...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-08-16
- Volume
- 379
- Issue
- 7
- Pages
- 633-644
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2887185538
- Cited by
- 1,475
- References
- 22
- Citations by year
- 2026: 158 · 2025: 172 · 2024: 178 · 2023: 175 · 2022: 197 · 2021: 219 · 2020: 210 · 2019: 141 · 2018: 20
- FWCI
- 116.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular risk factors, mortality, acute myocardial infarction, stroke, heart failure hospitalization, HbA1c, LDL cholesterol, albuminuria, smoking, blood pressure, Swedish National Diabetes Register, matched cohort comparison
- MeSH terms
- Adult, Albuminuria, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypercholesterolemia, Hypertension, Male, Middle Aged, Myocardial Infarction, Risk Factors, Smoking, Sweden, Cohort Studies, Body Mass Index, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
